Policy & Regulation
Elixirgen Therapeutics Inks Licensing Agreement for Its Novel COVID-19 Vaccine
8 October 2021 - - US-based biotechnology company Elixirgen Therapeutics, Inc has entered into an exclusive licensing agreement with a global pharmaceutical company (currently undisclosed) for the rights to commercialize its self-replicating RNA vaccine for COVID-19, called EXG-5003, on a worldwide basis (excluding Japan), the company said.

EXG-5003 is an intradermally-injected, temperature-controllable, self-replicating RNA vaccine expressing the receptor binding domain of the SARS-CoV-2 spike protein.

EXG-5003 is designed to induce robust cellular immunity to provide broad protection across variants. Elixirgen Therapeutics is currently dosing volunteers with EXG-5003 in a Phase 1/2 Clinical Trial in Japan that started in May 2021.

Additional terms of the agreement were not disclosed.

Elixirgen Therapeutics, Inc. is a clinical stage biotechnology company which is focused on cell and gene therapy and vaccine development.